Anticorps Polyclonal de lapin anti-c-MYC

• Phare
• Validé par KD/KO

c-MYC Polyclonal Antibody for FC, IF, IP, WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain et plus (4)

Applications

WB, IP, IF, FC, EMSA, CoIP, ChIP, ELISA

Conjugaison

Non conjugué

Publications

569

Avis (4)

N° de cat : 10828-1-AP

Synonymes

bHLHe39, c Myc, c-Myc, MRTL, MYC, Myc proto oncogene protein, Proto oncogene c Myc, Transcription factor p64

---

Galerie de données de validation

• 

  WB analysis of A549 using 10828-1-AP

  WB result of c-MYC antibody (10828-1-AP; 1:12000; incubated at room temperature for 1.5 hours) with sh-Control and sh-c-MYC transfected A549 cells.

• 

  WB analysis using 10828-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody) at dilution of 1:6000 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 10828-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody) at dilution of 1:6000 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 10828-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody) at dilution of 1:6000 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 10828-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody) at dilution of 1:6000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HL-60 using 10828-1-AP

  HL-60 cells were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of human placenta using 10828-1-AP

  human placenta tissue were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  IP experiment of MCF-7 using 10828-1-AP

  IP result of anti-c-MYC (IP:10828-1-AP, 4ug; Detection:10828-1-AP 1:1000) with MCF-7 cells lysate 1660 ug.

• 

  IF Staining of U2OS using 10828-1-AP

  Immunofluorescent analysis of (4% PFA) fixed U2OS cells using c-MYC antibody (10828-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-Phalloidin (red).

• 

  IF Staining of Saos-2 using 10828-1-AP

  Immunofluorescent analysis of (4% PFA) fixed Saos-2 cells using c-MYC antibody (10828-1-AP) at dilution of 1:400 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-phalloidin (red).

• 

  IF Staining of Saos-2 using 10828-1-AP

  Immunofluorescent analysis of (4% PFA) fixed Saos-2 cells using c-MYC antibody (10828-1-AP) at dilution of 1:400 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-phalloidin (red).

• 

  IF Staining of HEK-293 using 10828-1-AP

  Immunofluorescent analysis of (4% PFA) fixed HEK-293 cells using c-MYC antibody (10828-1-AP) at dilution of 1:400 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-Phalloidin (red).

• 

  FC experiment of HeLa using 10828-1-AP

  1X10^6 HeLa cells were intracellularly stained with 0.4 ug Anti-Human c-MYC (10828-1-AP) and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Isotype Control. Cells were fixed and permeabilized with Transcription Factor Staining Buffer Kit (PF00011).

---

Applications testées

• Résultats positifs en WB: cellules HT-29, cellules A549, cellules BxPC-3, cellules HeLa, cellules HepG2, cellules HL-60, cellules Jurkat, cellules Jurkat et cellules Raji, cellules Raji, cellules SH-SY5Y, cellules SW-1990, tissu placentaire humain
• Résultats positifs en IP: cellules MCF-7,
• Résultats positifs en IF: Saos-2 cells, cellules HEK-293, cellules U2OS
• Résultats positifs en cytométrie: cellules HeLa,

Dilution recommandée

• Western Blot (WB): WB : 1:2000-1:12000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunofluorescence (IF): IF : 1:200-1:800
• Flow Cytometry (FC): FC : 0.40 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 21 publications below
• WB: See 516 publications below
• IF: See 33 publications below
• IP: See 19 publications below
• CoIP: See 14 publications below
• ChIP: See 10 publications below

Informations sur le produit

10828-1-AP cible c-MYC dans les applications de WB, IP, IF, FC, EMSA, CoIP, ChIP, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: rat, Humain, porc, poulet, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: c-MYC Protéine recombinante Ag1263
• Nom complet: v-myc myelocytomatosis viral oncogene homolog (avian)
• Masse moléculaire calculée: 49 kDa
• Poids moléculaire observé: 62-65 kDa, 50 kDa
• Numéro d’acquisition GenBank: BC000141
• Symbole du gène: MYC
• Identification du gène (NCBI): 4609
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Function

c-Myc (also known as Myc), together with l-Myc and n-Myc, belongs to the Myc family of transcription factors. c-Myc has a basic helix-loop-helix leucine zipper domain and through heterodimerization can bind and regulate the transcriptional activity of genes, either by repression or activation. It is a key player in the regulation of cell growth and cell cycle progression and acts as a proto-oncogene.

Tissue specificity

c-Myc is ubiquitously expressed in almost all cell types and its expression positively correlates with tissue proliferative capacity. c-Myc is also expressed during embryogenesis and is upregulated in many cancer types.

Involvement in disease

·         Upregulated in many cancer types, especially in aggressive, poorly differentiated tumors.

·         Mutations in the MYC gene and breakpoint translocations within the MYC gene cause Burkitt lymphoma.

Isoforms

There are 3 different isoforms of c-Myc: c-Myc1, c-Myc2, and c-MycS (PMID: 16260605). They differ in molecular size, can be preferentially expressed during cell growth, and are reported to be functionally distinct.

Post-translational modifications

c-Myc is subject to various post-translational modifications, including phosphorylation, acetylation, and ubiquitinylation (PMID: 16987807), which regulate its activity.

Cellular localization

c-Myc localizes to the nucleus but can also be present in the cytoplasm of certain cancer types.

Publications

Species	Application	Title
human	WB	Nature; RIC-seq for global in situ profiling of RNA-RNA spatial interactions.; Authors - Zhaokui Cai
mouse	WB	Signal Transduct Target Ther; MDIG-mediated H3K9me3 demethylation upregulates Myc by activating OTX2 and facilitates liver regeneration; Authors - Jinpeng Du ; KD Validated
human	WB	Signal Transduct Target Ther; Overexpression of CIP2A is associated with poor prognosis in multiple myeloma.; Authors - Xuewen Liu
human	WB,IF	Gastroenterology; Nucleolar HEATR1 upregulated by mTORC1 signaling promotes hepatocellular carcinoma growth by dominating ribosome biogenesis and proteome homeostasis; Authors - Xiao-Mei Yang
human	WB	Cancer Cell; p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.; Authors - Alessandro Carugo ; KD Validated
	WB	Cell Metab; Efferocytosis induces macrophage proliferation to help resolve tissue injury.; Authors - Brennan D Gerlach ; KD Validated

Avis

The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.

---

FH

Molly (Verified Customer) (05-02-2023)

The antibody worked well for western blotting following the recommended protocol.

• Applications: Western Blot
• Primary Antibody Dilution: 1:2000
• Cell Tissue Type: Ewing sarcoma cell lines

FH

Anna-Maria (Verified Customer) (08-13-2019)

This antibody worked as expected for western blotting

• Applications: Western Blot,
• Primary Antibody Dilution: 1:1000
• Cell Tissue Type: Bladder cancer cell lines

FH

Christine (Verified Customer) (11-13-2018)

The antibody worked better than the Abcam c-Myc antibody. However, I did not get clear nuclear staining but rather a mix of nuclear staining with cytoplasmic staining. This could be due non-optimized conditions.

• Applications: Immunohistochemistry,
• Primary Antibody Dilution: 1 to 300
• Cell Tissue Type: Colon

FH

Claudio (Verified Customer) (12-14-2017)

We tested the antibody in IHC/IFL on mouse brain tumors that showed c-myc upregulation at the mRNA level.

• Applications: Immunohistochemistry, Immunofluorescence
• Primary Antibody Dilution: 100
• Cell Tissue Type: Mouse brain tumors with c-myc upregulation (determined at the mRNA level)

Produits associés

P53 Polyclonal antibody

10442-1-AP

MAX Polyclonal antibody

10426-1-AP

human BCL2 Polyclonal antibody

12789-1-AP

Cyclin D1 Monoclonal antibody

60186-1-Ig

Beta Catenin Polyclonal antibody

51067-2-AP

MYCN Polyclonal antibody

10159-2-AP

P21 Monoclonal antibody

60214-1-Ig